Sign up for news updates

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Evolving Standards of Care

Add ILCN as a preferred source
  • Expanding Efforts Help Address Disparities in Lung Cancer Care

    Expanding Efforts Help Address Disparities in Lung Cancer Care

    Evolving Standards of Care

    By Kara Nyberg, PhD Posted: August 21, 2020 A multitude of factors contribute to disparities in lung cancer care, including sex, race, education level, income, geographic region, and access to care. “There are some systemic barriers that make it difficult for people to obtain equitable treatment by race and class in the United States,” regardless…

  • An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival

    An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival

    Evolving Standards of Care

    By Mary Jo Fidler, MD Posted: August 21, 2020 At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program Plenary Session, an early look at data from the ADAURA trial revealed very promising results.1 This phase III randomized trial in patients with resected EGFR-mutated NSCLC compared post-operative osimertinib to placebo for stage IB-IIIA…

  • Expanding Efforts Help Address Disparities in Lung Cancer Care

    Expanding Efforts Help Address Disparities in Lung Cancer Care

    Evolving Standards of Care

    By Kara Nyberg, PhD Posted: August 19, 2020 A multitude of factors contribute to disparities in lung cancer care, including sex, race, education level, income, geographic region, and access to care. “There are some systemic barriers that make it difficult for people to obtain equitable treatment by race and class in the United States,” regardless…

  • Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

    Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

    Evolving Standards of Care

    Harpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 pandemic in how clinical trials are conducted, as well as the implications of these changes and what can be expected going forward. Q: How has…

  • Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice

    Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice

    Evolving Standards of Care

    By Kara Nyberg, PhD Posted: June 24, 2020 Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically improve patient outcomes. Up to 85% of patients with lung cancer harbor potentially actionable driver mutations, and matching targeted therapy to druggable alterations in the first-line setting prolongs survival…

  • Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A With Dr. Benjamin Movsas

    Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A With Dr. Benjamin Movsas

    Evolving Standards of Care

    Posted: June 24, 2020 The IASLC Lung Cancer News spoke with Benjamin Movsas, MD, regarding the evolution of patient-reported outcomes (PROs) for lung cancer. Dr. Movsas is the co-chair of the Patient-Centered Outcomes Research Committee for the NRG Oncology Cooperative Group, chair of the radiation oncology department at the Henry Ford Cancer Institute in Michigan,…

  • TTFields in Unresectable MPM: STELLAR Results in Practice

    TTFields in Unresectable MPM: STELLAR Results in Practice

    Evolving Standards of Care

    By Giovanni Luca Ceresoli, MD Posted: June 24, 2020   Dr. Giovanni Luca Ceresoli Tumor-treating fields (TTFields) are a noninvasive, regional treatment based on the delivery of low-intensity alternating electric fields by transducer arrays applied to the patient’s skin surrounding the tumor.1 TTFields extend survival in glioblastoma and are U.S. Food and Drug Administration (FDA)…

  • Stage IIIA NSCLC: A Review of Recent and Ongoing Trials Trial

    Stage IIIA NSCLC: A Review of Recent and Ongoing Trials Trial

    Evolving Standards of Care

    By Mariano Provencio, MD, PhD Posted: June 24, 2020 Data can help inform change to standard of care, but at what point do we say enough data is enough and move forward with combination therapy as the new standard of care? Stage IIIA disease accounts for approximately 15% to 20% of all lung cancers. This…

  • TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the Constellation

    TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the Constellation

    Evolving Standards of Care

    By Paul Baas, MD, PhD, and Cornedine J. de Gooijer, MD Posted: June 24, 2020 Recently, a manuscript by Ceresoli et al. was published in The Lancet Oncology.1 The study states that the use of tumortreating fields (TTFields) is a major improvement in the treatment of patients with mesothelioma compared to previous standards.2 Herein, we…

  • Multidisciplinary Tumor Boards: Approaches Across Different Institutions

    Multidisciplinary Tumor Boards: Approaches Across Different Institutions

    Evolving Standards of Care

    Posted: June 24, 2020 In an effort to provide its audience with information about best practices for multidisciplinary communication, ILCN will be highlighting the approaches of different international institutions. From sharing information on who is included in discussions to the results of formalized processes, authors from each institution provide numerous organizational and clinical pearls. Multidisciplinary…

View ILCN Archives

Provider Resources

Popular Articles